Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
  • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
  • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/74—Biological properties of particular ingredients
  • A61K2800/75—Anti-irritant

Definitions

• the present invention relates to certain uses of compounds of the formula 1 or of mixtures of two or more different compounds of the formula 1.
• the invention also relates to selected compounds of formula 1 which were previously unknown.
• a first aspect of the present invention relates to the use of a compound of the formula 1 or a mixture of two or more different compounds of the formula 1 as a cosmetic agent for inhibiting substance P-induced release of histamine from mast cells or for producing a medicament for inhibiting substance P induced histamine release from mast cells.
• n 0, 1, 2 or 3,.
• n 0, 1 or 2,.
• n 1 or 2 each in pairs R 1 and R 2 each denote H or together represent a further chemical bond (such as in cinnamic acid derivatives);
• each Y independently of the others, denotes OH, OAlkyi or OAcyl,
• R 3 H or alkyl (in particular -CH 3 and linear or branched alkyl chains with 2 to 30 C atoms)
• R 3 H also stands for the corresponding pharmaceutically acceptable sentences.
• mast cells play an important role in allergic and inflammatory processes, since after appropriate stimulation they release mediators such as histamine, which are largely responsible for symptoms such as itching (pruritus), pain or reddening reactions. are.
• mediators such as histamine, which are largely responsible for symptoms such as itching (pruritus), pain or reddening reactions. are.
• Countless studies have shown that the neuropeptide substance P, which is released by nerve endings in the skin, leads to a degranulation of mast cells.
• substance P can be considered one of the most important links between the peripheral nervous system and symptoms such as inflammatory processes, itching and pain.
• mast cells Various forms of Urtikaha have one thing in common, namely the activation of a special cell type, the so-called mast cells.
• Mast cells could also be called the “fire brigade” or “border police” of the human body. They are particularly common where we are in direct contact with our environment, that is, in addition to the skin, also in the mucous membranes of the gastrointestinal tract and the respiratory tract.
• the activation of the mast cells by different mediators can be accompanied by severe inflammatory reactions, itching and severe allergic reactions up to anaphylactic shock.
• the mast cells manufacture a large variety of products, including histamine.
• neuropeptides release itching substances (so-called neuropeptides).
• neuropeptides eg substance P
• mast cell activators so that the stimulation of nerves by mast cells results in the stimulation of mast cells by nerves.
• Mast cells are preferred in the skin and mucous membranes localized in the immediate vicinity of vessels and nerves. No wonder that communication between the "neighbors" mast cell, vascular cell and nerve fiber works excellently.
• certain compounds of the formula 1 or mixtures of two or more different compounds of the formula 1 are not only used for inhibiting substance P-induced release of histamine from mast cells may, but more generally for the treatment of or prevention of itching (pruritus), reddening of the skin, wheals and / or allergic skin reactions (as well as for the production of appropriate medicines).
• itching is not only associated with the above-mentioned mechanisms but also with dry skin, aging skin, mechanically, chemically or skin stressed by sunlight.
• Psychological factors such as anxiety or stress can also cause itching.
• Soaps, cleaning agents and solvents which put a lot of strain on the skin, can lead to a disturbed hydrolipid film and consequently cause itching reactions.
• Itching can also occur during the healing process of injuries or burns (e.g. after shaving or after sunburn), so that the use of cosmetic formulations that prevent or relieve itching can also help to maintain an optimal physiological condition of the skin.
• the wide range of cosmetic products that are used for aging skin.
• Compounds of formula 1 or the mixtures of two or more different compounds of formula 1 can be present as part of an optionally post-treated plant extract.
• the optionally aftertreated plant extract can be an extract from plants of the genus Avena, Dianthus, Silene or Melandrium, in particular oat extracts or clove extracts.
• a plant extract is aftertreated, this preferably ensures that the proportion of one or more compounds of the formula 1 is extracted relative to the proportion of others in comparison with the untreated extract. Connections is increased.
• an isolated and purified compound of the formula 1 or an isolated and purified mixture of two or more different compounds of the formula 1 for the stated purposes.
• an aftertreatment can be seen in which the proportion of compounds of the formula 1 is increased relative to the proportion of other extracted compounds.
• the present invention also relates to selected compounds of the formula 1 which can and have not hitherto been used for the purposes mentioned were known. These new and inventive compounds can be found in the attached tables.
• mast cells include, for example, Dinathumcromogycat, Verapamil,
• Tranilast N- (3,4-dimethoxycinnamoyl) anthranilic acid, a natural one in the Chinese medicinal plant
• Nandina domestica occurring anthranilic acid amide Nandina domestica occurring anthranilic acid amide. that however
• Tranilast in allergic reactions such as bronchial asthma, allergic rhinitis, allergic conjunctivitis, food allergies, urticaria or atopic dermatitis
• bronchial asthma bronchial asthma
• allergic rhinitis allergic conjunctivitis
• food allergies urticaria or atopic dermatitis
• M.Koj ⁇ ma et al. Oyo Yakuri 28 (4), 623-628 (1984)
• Azuma et al. Br. J. Pharmacol. Nol.58, p.483-488, ( 1976); Koda et. Al., Int. Archs. Allergy appl. Immun. Vol.
• Tranilast inhibits the antigen (DNP-ascaris; monoclonal ' IgE antibodies with 2,4-dinitrophenyl specificity) induced histamine release from mast cells in the. Concentration range from 10 "3 to 10 " 5 M. A 50% inhibition of histamine release could be achieved at a concentration of approx. 10 "4 M. The influence of other anthranilic acid amides on the inhibition of the release of histamine from mast cells was demonstrated in the publication, however, is not described.
• Hachisuka et al. investigated the influence of various active substances on the inhibition of substance P induced. Release of histamine from mast cells.
• the effectiveness of disodium cromogylcat, ketotifen and tranilast was compared here. A 50% inhibition of substance P-induced histamine release could only at a relatively high concentration of about 10 "3 M, can be obtained. With a molecular weight of tranilast of 327 corresponds to 10" 3 M at a concentration of 327 ⁇ g / ml or 327 ppm.
• the value of DSCG Disinathumcromoglycat
• Other anthranilamides were not investigated in this research in detail. '
• Anthranilic acid amides are described as ingredients of certain plants, such as oats (Avena sativa) or cloves (Dianthus sp ⁇ ).
• the avenanthramids of oats are acid amides consisting of unsubstituted or substituted anthranilic acid partial structures and unsubstituted or substituted cinnamic acid partial structures, whereas the acid amides in clove species are essentially composed of anthranilic acid and benzoic acid partial structures.
• Plant physiological studies showed that both the so-called avenanthramides of oats and the so-called dianthramides in cloves as.
• Phytoalexins act and are formed from the 'plant according to microbial attack as part of a defense mechanism.
• the work mentioned should make particularly effective compounds available, preferably in highly pure form, so that they can be used in pharmaceutical or cosmetic products free of any toxicologically or dermatologically critical secondary components (synthesis of by-products or plant extract secondary components).
• Example 2 Catalytic hydrogenation of core-unsubstituted or substituted cinnamoylanthranilic acid derivatives for the corresponding dihydro compound (8, Table 1a) using the example of N- (4-hydroxycinnamoyl) anthranilic acid (Avenanthramide D, 10)
• the aqueous solution is stirred in portions (2 kg) with Amberlite XAD-16 (270 g).
• the adsorber resin is separated off via a frit, washed with water and eluted with methanol / water 1: 1 (v / v).
• the combined eluates are freed from the solvent in vacuo. Dry extract: 8.5 g, ⁇ Avenanthramide A, B & C. 1.2%.
• This dry extract is taken up in ethanol / water 1: 1 (v.:v) and adjusted to an avenanthramide content ⁇ A, B & C of 500 ppm by dilution with ethanol / water 1: 1 (v: v).
• the synthetically produced avenanthramides and dianthramides with the formulas 2 to 29 were mixed with buffer medium to the final concentrations (0.5; .5 and 50 ppm, see Tables 1a / 1 b), corresponding to an ethanol Concentration of 0.5; Diluted 0.05 or 0.005% (v / v). Calcium chloride, which served as a positive control. also diluted with buffer medium so that solutions in the concentration range of 10 "8 to 10 " 2 M were available.
• Test system The final test solutions were incubated for 2 minutes in the presence of substance P and the reference substance (CaCl 2 ) or the sample to be tested (incubation temperature: 37 ° C). The cells in absentia served as the zero sample. of substance P and reference or sample substance were incubated.
• reaction solutions were first freed from cell components by centrifugation. The histamine in the supernatant was then derivatized with OPT and the fluorescence of the solutions was determined photometrically (Fluorometer Cytofluor 2350).
• Calcium chloride inhibited the substance P-induced release of histamine from mast cells depending on the concentration. A 50% inhibition was possible with a calcium chloride concentration of 639 ⁇ M can be achieved. This corresponds to the expected value and thus validates the underlying test design
• the samples GS-101100-A and GS-101 100-B were mixed with buffer medium to the final concentrations (0.5; 5 and 50 ppm, see Table 2), corresponding to an ethanol concentration of 0.1; 1 or 10% (v / v). Diluted. Calcium chloride, which served as a positive control. ⁇ was also diluted with 'buffer medium so that solutions in the concentration range of 10 "5 and 10" 2 M were available.
• Test system The final test solutions were incubated in the presence of substance P and the reference substance (CaCl 2 ) or the sample to be tested for 2 minutes (incubation temperature: 37 ° C.). Cells which were incubated in the absence of substance P and reference or sample substance served as the zero sample.
• reaction solutions were first freed from cell components by centrifugation.
• the histamine in the supernatant was then derivatized with OPT and the fluorescence of the solutions was determined photometrically (fluorometer cytofluor 2350).
• Calcium chloride inhibited the substance P-induced release of histamine from mast cells depending on the concentration. A 50% inhibition could be achieved within this test series with a calcium chloride concentration of 432 ⁇ M. This corresponds to the expected value and thus validates the underlying test design
• Tranilast higher activity (see Table 1. Substances 11- 13) also observed in anthranilamides with only one free hydroxyl function in Anthranilklarerest, particularly 'in their arrangement in the 4-position of the anthranilic acid residue.
• the percentage rate of histamine release inhibition at a dosage of 50 ppm is in the range of 30-36.%.
• Substances 2-13 are exemplary representatives of a preferred subgroup of compounds of formula 1, for which the following applies:
• X is selected at least once from the group consisting of OH or OAcyl
• Y is selected at least once from the group consisting of OH and OAcyl.
• Substances 14-19 which also include tranilast (substance 15), exert an inhibiting effect with regard to histamine release that is no longer satisfactory in comparison with the aforementioned substances.
• Tranilast The comparatively low effectiveness of Tranilast is consistent with the studies by Hachisuka et al. (Arch Dermatol Res Vol.280, p.158-162; 1988). The authors were only able to determine a 50% inhibition of histamine release at a concentration of 327 ppm. The alkylation of the vicinal hydroxyl functions in the cinnamic acid or dihydrocinnamic acid part is apparently accompanied by a significant reduction in effectiveness.
• Table 2 shows an example of the results of the direct comparison of an oat extract (see Table 2: sample GS10100-A, oat extract standardized to 500 ppm ⁇ avenanthramides 3, 4 and 5; formulas: see also Table 1a;) and a synthetic reconstitution containing all 500 ppm ⁇ synthetic avenanthramides 3, 4 and 5 (sample GS10100-B, see also Table 1a,) in exactly comparable proportions.
• the direct comparison of the two samples proves that the inhibition of substance-P-induced release of histamine from mast cells is essentially caused by the avenanthramides 3, 4 and 5 contained in the oat extract (see Table 1a).
• Release of histamine from mast cells can be used and thus prevent inflammation, reddening and itching reactions and / or can help to alleviate them.
• Tables 3 and 4 exemplarily list previously unknown and, on the other hand, already known substances, which are preferably used as histamine release inhibitors. Substances 2-29 can already be found in Tables 1a and 1b, substances 30- 80 are not found there.
• Way can be used.
• the compounds or mixtures which can be used according to the invention can be high-purity synthetic products, pure isolates from plant extracts such as, for example, from oats (Avena sativä) or clove species (Dianthus spec.), Or specific extract fractions from plants such as oats (Avena sativä). ' or cloves (Dianthus sp.) act, which contain the preferred compounds of the invention in high concentration.
• R 3 -CH 3 , linear or branched alkyl radicals with chain lengths C2 to 30).
• acylated or alkylated compounds of formula 1 penetrate very well into deeper skin layers when applied topically.
• Concentration range from 0.0001 to 10 wt .-% and preferably in the concentration range from 0.001 - 1 wt .-%, based on the Total mass of a ready-to-use cosmetic or pharmaceutical end product.
• histamine release inhibitors used according to the invention and in particular those of the avenanthramide and dianthramide types, leave
• histamine release inhibitors according to the invention with other active ingredients, for example with other possibly. even synergistically enhancing histamine release inhibitors or with anti-inflammatory and / or itching and redness reducing substances,
• the histamine release inhibitors according to the invention containing cosmetic and / or dermatological / keratological
• 20 formulations can otherwise be composed as usual and for the treatment of the skin and / or. the hair in the sense of a dermatological / keratological treatment or a treatment in the sense of nourishing cosmetics. But they can also be used in make-up products in decorative cosmetics.
• Containing histamine release inhibitors can also contain other anti-inflammatory or anti-redness and itching agents. It can be all suitable or customary for cosmetic and / or dermatological applications
• anti-inflammatory or redness and itch relieving active ingredients are used.
• steroidal anti-inflammatory substances of the corticosteroid type such as hydrocortisone, dexamethasone, dexamethasone phosphate, methylprednisolone or cortisone, the list being expandable by adding further steroidal anti-inflammatories.
• Nonsteroidal anti-inflammatories can also be used.
• Oxicams such as piroxicam or tenoxicam should be mentioned as examples; Salicylates such as aspirin, disalcid, sölprin or fendosal; Acetic acid derivatives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, or clindanac; Fenamates such as mefenamic, meclofenamic, flufenamic or niflumic; Propionic acid derivatives such as ibuprofen, naproxen, benoxaprofen or pyrazoles such as phenylbutazone, oxyphenylbutazone, febrazone or azapropazone.
• Salicylates such as aspirin, disalcid, sölprin or fendosal
• Acetic acid derivatives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, or clinda
• Natural anti-inflammatory or redness and itch relief substances can be used.
• Plant extracts, special highly effective plant extract fractions and highly pure active substances isolated from plant extracts can be used. Extracts, fractions and active substances from chamomile, aloe era, Commiphora species, Rubia species, willow trees, willowherb, and pure substances such as bisabolol, apigenin-7-glucoside, boswellic acid, phytosterols, are particularly preferred.
• the formulations containing histamine release inhibitors can also mixtures of two or more other anti-inflammatory agents.
• Containing histamine release inhibitors can also contain active ingredients for preservation, whereby all preservatives suitable or customary for cosmetic and / or dermatological applications can be used.
• Preservatives are advantageously selected, such as benzoic acid, its esters and salts, propionic acid and its salts, salicylic acid and its salts, 2,4-hexadienoic acid (sorbic acid) and its salts, formaldehyde and Paraformaldehyde, 2-hydroxybiphenyl ether and its salts, 2-zinc sulfidopyridine-N-oxide, inorganic sulfites and bisulfites, sodium iodate, chlorobutanol, 4-hydroxybenzoic acid, its salts and esters, dehydratcetic acid, formic acid, 1, 6-bis (4-amidino-2 - bromophenoxy) -n-hexane and its salts, sodium salt 'of the Ethylquecksilber- (II) -
• Additional antibacterial or antifungal agents can also be used particularly advantageously in the cosmetic preparations which contain histamine release inhibitors according to the invention, it being possible to use all antibacterial or antifungal agents which are suitable or customary for cosmetic and / or dermatological applications.
• the products that are relevant for cosmetics such as triclosan, climbazole, octoxyglycerol, octopirox (1-hydroxy-4-methyl-6- (2,4,4-trimethylpentyl) -2 (1 H), are particularly advantageous.
• the synergistic mixtures of histamine release inhibitors according to the invention can also be used particularly advantageously in combating body odor in combination with antiperspirant active ingredients (antiperspirants).
• antiperspirant active ingredients are aluminum salts such as aluminum chloride, aluminum chlorohydrate, nitrate, sulfate, acetate, etc.
• zinc, magnesium and zirconium compounds can also be advantageous.
• essentially the aluminum salts and - to a somewhat lesser extent - aluminum / zirconium salt combinations have prevailed.
• other substances are also possible, such as a) protein-precipitating substances such as formaldehyde, glutaraldehyde, natural and synthetic tannins and trichloroacetic acid, which cause a superficial occlusion of the sweat glands b) local anesthetics (including dilute solutions of eg lidocaine, prilocaine) or mixtures of such substances), which switch off by blocking the peripheral nerve paths, the sympathetic supply to the sweat glands, c) zeolites of the X, A or Y type.
• protein-precipitating substances such as formaldehyde, glutaraldehyde, natural and synthetic tannins and trichloroacetic acid, which cause a superficial occlusion of the sweat glands
• local anesthetics including dilute solutions of eg lidocaine, prilocaine or mixtures of such substances
• botulinum toxin toxin of the bacterium Chlostridium botulinum
• acetylcholine a pathologically increased sweat secretion, and its effect on irreversibly blocking the release of the for Sweat secretion-relevant transmitter substance acetylcholine is based.
• a combination with (metal) chelators can also be advantageous in the cosmetic preparations which contain histamine release inhibitors according to the invention, it being possible to use all metal chelators which are suitable or customary for cosmetic and / or dermatological applications.
• (Metal) chelators which are preferably to be used include -hydroxy fatty acids, phytic acid, lactoferrin; ⁇ -hydroxy acids such as Citric acid, lactic acid and malic acid as well as humic acids. Bile acids, bile extracts, bilirubin, biliverdin or EDTA, EGTA and their derivatives.
• the formulations according to the invention containing histamine release inhibitors are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics and dermatics.
• Cosmetic and dermatological preparations which contain a mixture according to the invention and additionally act as sunscreens offer particular advantages. These preparations advantageously contain at least one UVA filter and / or at least one UVB filter and / or at least one. inorganic pigment.
• the preparations can be in various forms, such as are usually used for this type of preparation. So For example, you can use a solution, an emulsion of the water-in-oil (W / O) or oil-in-water (O / W) type, or a multiple
• Emulsions for example of the water-in-oil-in-water (W / O W) type, a gel, a hydrodispersion, a solid stick or an aerosol.
• W / O W water-in-oil-in-water
• preparations which contain histamine release inhibitors according to the invention can advantageously be combined with substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. Is 0.01% by weight to 40% by weight, preferably 0.1% to 10% by weight, in particular 1.0 to 5.0% by weight, based on the total weight of the preparations, for cosmetic preparations to provide that protect the hair or skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair.
• the preparations according to the invention contain UVB filter substances, they can be oil-soluble or water-soluble.
• Advantageous oil-soluble UVB filters are e.g. 3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor. , 3-benzylidene camphor; 4
• Aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
• Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
• Esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4isopropylbenzyl) ester, salicylic acid homomenthyl ester, derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone , 2,2'-dihydroxy-4-methoxybenzophenone;
• Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-eth
• Advantageous water-soluble UVB filters are, for example, salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and the sulfonic acid itself; sulfonic acid Derivatives of - benzophenones, preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and their salts; sulfonic acid
• Sulfato compounds for example the corresponding sodium
• UVB filters which in combination with the inventive ⁇ histamine release inhibitors can be used ', should of course not be construed as exhaustive. It can also be advantageous to use UVA filters, as are usually contained in cosmetic preparations. These substances are preferably derivatives. dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione and 1-phenyl-3- (4'-isopropylphenyl) propane-1, 3-dione. The amounts used for the UVB combination can be used.
• the histamine release inhibitors according to the invention can advantageously also be combined in cosmetic preparations with other cosmetic auxiliaries, as are usually used in such preparations, for example antioxidants, perfume oils, anti-foaming agents, dyes, pigments which have a coloring effect, thickeners, Surface-active substances, emulsifiers, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual components of a cosmetic formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
• other cosmetic auxiliaries for example antioxidants, perfume oils, anti-foaming agents, dyes, pigments which have a coloring effect, thickeners, Surface-active substances, emulsifiers, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual components of a cosmetic formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvent
• compositions of one or more caring animal and / or vegetable fats and oils such as olive oil, sunflower oil, refined soybean oil ,. Palm oil, sesame oil ', rapeseed oil, almond oil, borage oil, evening primrose oil, coconut oil, shea butter, jojoba oil, sperm oil, beef tallow, neat's foot oil. and lard as well as other caring ingredients such as. for example fatty alcohols with 8-30 C atoms.
• the fatty alcohols used can be saturated or unsaturated or linear or branched.
• the fatty alcohols preferably derive from natural fatty acids, whereby they usually come from the corresponding ones. Esters of fatty acids can be produced by reduction. Fatty alcohol fractions can also be used, which by reduction from naturally occurring fats and fatty oils such as beef tallow, peanut oil, rape oil, cottonseed oil, soybean oil, Sunflower oil, palm kernel oil, linseed oil, corn oil, castor oil, rapeseed oil, sesame oil, cocoa butter and coconut oil are produced.
• natural fatty acids such as beef tallow, peanut oil, rape oil, cottonseed oil, soybean oil, Sunflower oil, palm kernel oil, linseed oil, corn oil, castor oil, rapeseed oil, sesame oil, cocoa butter and coconut oil are produced.
• Care substances that can be combined excellently with the .histamine release inhibitors according to the invention also include
• Ceramides where one understands ceramides N-acylsphingosine (fatty acid amides of sphingosine) or synthetic analogues of such lipids (so-called pseudo-ceramides) that significantly improve the water retention of the .Stratum Comeum.
• Phospholipids for example soy lecithin, egg lecithin and cephalins
• Petroleum jelly, paraffin and silicone oils include, inter alia, dialkyl and alkylaryl 'such as dimethyl polysiloxane and methylphenyl polysiloxane and alkoxylated and quaternized derivatives
• Animal and / or vegetable protein hydrolyzates can advantageously also be added to the formulations according to the invention containing histamine release inhibitors.
• elastin, collagen, keratin, milk protein, soy protein, etc. are particularly advantageous.
• a cosmetic or dermatological preparation containing histamine release inhibitors according to the invention is a solution or lotion
• the following can be used as solvents: Water or aqueous solutions;
• esters of fatty acids with alcohols of low C number e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
• Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether,.
• Water can also be a component of alcoholic solvents.
• Containing histamine release inhibitors can also contain antioxidants, it being possible to use all antioxidants which are suitable or customary for cosmetic and / or dermatological applications.
• the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-camosin, D-camosin, L-camosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g.
• ⁇ -carotene, ⁇ -carotene, lycopene and their derivatives, lipoic acid and their derivatives (e.g. dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (e.g.
• thioredoxin glutathione, cysteine, cystine , Cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and Lauryi, palmitoyl, oleyl, ⁇ - Linoleyl, cholesteryl and glyceryl esters) as well as their salts, diiauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
• buthioninsulfoximines homocystionesulfoximine, butocysteinesulfoximine, butyl , Heptathionine sulfoximine
• furthermore (metal) chelators for example ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin, ⁇ -hydroxy acids (for example citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin , EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g.
• zinc and its derivatives e.g. ZnO, ZnS04
• selenium and its derivatives e.g. selenium methionine
• stilbenes and their derivatives e.g. stilbene oxide, trans-stilbene oxide
• the derivatives salts , Esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids
• Containing histamine release inhibitors can also contain vitamins and precursors, wherein all vitamins or precursors suitable or customary for cosmetic and / or dermatological applications can be used.
• vitamins and vitamin precursors such as tocopherols, vitamin A, niacinic acid and niacinic acid amide, further vitamins of the B complex, in particular biotin and vitamin C.
• Panthenol and its derivatives are also preferably used within this group. the esters and ethers of panthenol as well as cationically derivatized panthenols such as panthenol triacetate, panthenol monoethyl ether and its monoacetate and cationic panthenol derivatives.
• Cosmetic preparations containing histamine release inhibitors can also. Contain active ingredients with skin lightening effects. According to the invention this can all appropriate ⁇ or conventional skin-lightening agents are used for cosmetic and / or dermatological applications.
• advantageous skin-lightening active ingredients are kojicacid, hydroquinone, arbutin, ascorbic acid, magnesium ascorbyl phosphate, licorice root extracts and their constituents glabridine or licochalkone A, or extracts from Rumex and Ramulus types, extracts from jaw types (Pinus) or extracts from Vitis types, among others contains skin-lightening stilbene derivatives.
• Containing histamine release inhibitors can also contain active ingredients with a tanning effect. It can be used so far all 'customary and suitable for cosmetic and / or dermatological applications or skin-tanning agents.
• Dihydroxyacetone (DHA; 1,3-dihydroxy-2-propanone) may be mentioned here as an example. DHA can exist in both monomeric and dimeric form, the proportion of dimers predominating in crystalline form.
• Containing histamine release inhibitors may also contain mono-di : and oligosaccharides such as glucose, galactose, fructose, mannose, fructose and lactose.
• Cosmetic preparations according to the invention may also contain mono-di : and oligosaccharides such as glucose, galactose, fructose, mannose, fructose and lactose.
• Histamine release inhibitors can also contain
• Contain plant extracts which are usually produced by extraction of the entire plant, but in individual cases also exclusively from flowers and / or leaves, wood, bark or roots of the plant.
• plant extracts that can be used according to the invention, reference is made in particular to the extracts that are listed in the table beginning on page 44 of the 3rd edition of the guide to the declaration of ingredients of cosmetic products, published by the Industry Association for Personal Care and Detergents (IKW), Frankfurt.
• the extracts from aloe, witch hazel, algae, oak bark, willowherb, nettle, dead nettle, hops, chamomile, yarrow, arnica, calendula, burdock root, horsetail, white dome, linden flowers, almond, spruce needle, horse chestnut, sandalwood, juniper are particularly advantageous , Mango, apricot, orange, lemon, lime, grapefruit, apple, green
• the inventive compositions include lower alcohols such as ethanol and isopropanol, but also polyhydric alcohols such as ethylene glycol, propylene glycol and butylene glycol are preferred, both as the sole extractant and in mixtures with water.
• the plant extracts can be used both in pure and in diluted form.
• Histamine release inhibitors contain, especially if crystalline or microcrystalline solids, for example inorganic micropigments are to be incorporated into the preparations according to the invention, can also contain anionic, cationic, nonionic and / or amphoteric surfactants.
• Surfactants are amphiphilic substances that can dissolve organic, non-polar substances in water.
• the hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO " , -OS0 3 2" , -S0 3 " , while the hydrophobic parts generally represent ' non-polar hydrocarbon residues.
• Surfactants are generally classified according to Art and charge of the hydrophilic part of the molecule. There are four groups:
• Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In aqueous solution, they form positively charged organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave in aqueous solution like anionic or cationic surfactants depending on the pH. In a strongly acidic medium, they have a positive charge and in alkaline medium a negative 'charge. In the neutral pH range however, they are zwitterionic. Polyether chains are typical of non-ionic surfactants. Non-ionic surfactants do not form ions in an aqueous medium.
• Anionic surfactants to be used advantageously are acylamino acids (and their salts), such as
• Acylglutamates for example sodium acylglutamate, di-TEA-palmitoyl aspartate and sodium capryl / capringlutamate,
• Acyl peptides for example palmitoyl-hydrolysed milk protein, sodium cocoyl-hydrolysed soya protein and sodium / potassium
• Sarcosinates for example myristoyl sarcosine, TEA lauroyl sarcosinate, sodium lauroyl sarcosinate and
• Carboxylic acids and derivatives such as
• Ester carboxylic acids for example calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauramide carboxylate,
• Ether carboxylic acids for example sodium laureth-13 " carboxylate and sodium PEG-6 cocamide carboxylate,
• Phosphoric acid esters and salts such as , for example, DEA-oleth-10-phosphate and dilaureth-4-phosphate,
• Acyl isothionates e.g. Sodium / ammonium cocoysethionate
• Alkyl sulfonates for example sodium coconut monoglyceride sulfate, sodium C 12-1 olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate,
• Sulfosuccinates for example dioctyl sodium sulfosuccinate, disodium la ⁇ reth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate
• Alkyl ether sulfate for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C12-13 pareth sulfate,
• Cationic surfactants to be used advantageously are '
• Quaternary surfactants contain at least one N atom that is covalently linked to 4 alkyl or aryl groups. Regardless of the pH value, this leads to a positive charge.
• Alkyl betaine, alkyl amidopropyl betaine and alkyl aminopropyl hydroxysulfain are advantageous.
• the cationic surfactants used can also preferably be selected from the group of the quaternary ammonium compounds, in particular benzyltrialkylammonium chlorides or bromides, such as, for example, benzyldimethylstearylammonium chloride, furthermore
• Alkyltrialkylammoniur ⁇ salts for example
• Alkylamidethyltrimethylammonium ether sulfates alkylpyridinium salts, for example lauryl or cetylpyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyldimethylamine oxides or
• Alkylaminoethyldimethylamine 'Advantageously be used particularly cetyltrimethylammonium salts.
• Acyl- / dialkylethylenediamine for example sodium acylamphoacetate, disodium acylamphodipropionate, disodium alkylamphodiacetate,
• N-alkylamino acids for example aminopropylalkylglutamide.
• Alkylaminopropionic acid sodium alkylimidodipropionate and lauroampho-carboxyglycinate.
• Alkanolamides such as Cocamide MEA DEA / MIPA
• Amine oxides such as Cgcoamidopropylaminoxid
• Esters which are formed by esterification of carboxylic acids with ethylene oxide, glycerol, sorbitan or other alcohols,
• - ethers for example ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, - ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated cholesterols, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated lanolin, ethoxylated / propoxylated polysiloxanes, propoxylated POE ethers and alkyl polyglycosides such as lauryl glucoside, decyl glycoside. undCocoglycosid.
• Polyglycerol esters diglycerol esters, monoglycerol esters
• Methyl glucose esters esters of hydroxy acids
• the surface-active substance can be present in a concentration between 1 and 98% by weight in the formulations according to the invention containing histamine release inhibitors, based on the total weight of the preparations.
• Cosmetic or dermatological preparations which contain histamine release inhibitors according to the invention can also be present as emulsions.
• esters of fatty acids with alcohols with a low C number for example with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids with a low C number or with fatty acids; benzoates;
• silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
• Esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids are advantageously used
• Chain length of 3 to 30 carbon atoms from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms.
• Preferred ester oils are isopropyl myristate,
• the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also fatty acid triglycerides, especially the triglycerol esters, saturated and / or. unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
• the fatty acid triglycerides can be advantageous, for example
• oils are selected from the group of synthetic, semi-synthetic and natural oils, e.g. Olive oil, sunflower oil, soybean oil, peanut oil,
• Rapeseed oil almond oil, palm oil, coconut oil, palm kernel oil and the like.
• the oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol,
• Isotridecyl isononanoate isoeicosan, 2-ethylhexyl cocoate, C 12-15 - alkyl benzoate, caprylic-capric acid triglyceride, dicaprylyl ether.
• Particularly advantageous' are mixtures of C 12-15 -alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C 12-15 -alkyl benzoate and isotridecyl isononanoate and mixtures of C 12- i 5 alkyl benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
• the hydrocarbons paraffin oil, squalane and squalene can be used advantageously.
• the oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
• Cyclomethicone eg decamethylcyclopentasiloxane
• other silicone oils can also be used advantageously, for example undecamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane). Mixtures of cyclomethicone and isotridecyl isononanoate, cyclomethicone and 2-ethylhexyl isostearate are also particularly advantageous.
• the aqueous phase of preparations in the form of an emulsion which may contain histamine release inhibitors according to the invention include: alcohols, diols or polyols of low C number, and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether , Propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and similar products, furthermore alcohols of low C number, for example ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which or which are advantageously chosen can be selected from the group silicon dioxide, aluminum silicates, Polysaccharides or their derivatives, e.g.
• Hyaluronic acid, xanthan gum, hydroxypropylmethyl cellulose,. particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group of so-called carbopoles, for example carbopoles of types 980, 981, 1382, 2984, 5984, in each case individually or in combination.
• Preparations which are present as an emulsion and which contain histamine release inhibitors according to the invention advantageously comprise one or more emulsifiers.
• 0 / W emulsifiers can, for example, advantageously be selected from the group of polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, e.g .:
• alkyl ether sulfates of the general formula R-0 - (- CH 2 -CH 2 -0-) n - S0 3 -H,
• the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers selected are particularly advantageously selected from the group of substances with HLB values of 11-18, very particularly advantageously with HLB values of 14.5-15.5 provided that 'the t O W emulsifiers have saturated Have radicals R and R '. If the O / W emulsifiers have unsaturated radicals R and / or R ', or if there are isoalkyl derivatives, then . The preferred HLB value of such emulsifiers is also lower or higher.
• fatty alcohol ethoxylates from the group of the ethoxylated stearyl alcohols, cetyl alcohols, cetylstearyl alcohols (cetearyl alcohols).
• cetyl alcohols cetylstearyl alcohols
• cetearyl alcohols cetearyl alcohols
• the sodium laureth-11 carboxylate can advantageously be used as the ethoxylated alkyl ether carboxylic acid or its salt.
• Sodium laureth 1-4 sulfate can advantageously be used as alkyl ether sulfate.
• Polyethylene glycol (30) cholesteryl ether can advantageously be used as the ethoxylated cholesterol derivative. become.
• Polyethylene glycol (25) soyasterol has also proven itself.
• polyethylene glycol glycerol fatty acid esters from the group consisting of polyethylene glycol (20) glyceryl laurate,
• W / O emulsifiers can be used. become:. Fatty alcohols with 8 to 30 carbon atoms; Monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms, diglycerol esters of saturated and / or unsaturated, branched and / or unbranched "alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms, Monoglycerol ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, diglycerol ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, propylene glycol esters of saturated and / or unsaturated, branched and
• W / O emulsifiers are glyceryl monostearate, glyceryl monoisostearate, glyceryl monomyristate, glyceryl monooleate, diglyceryl monostearate, diglyceryl monoisostearate, propylene glycol monostearate, propylene glycol monoisostearate,
• Glyceryl monocaprinate Glyceryl monocaprylate
• a substance of formula 1 according to the invention can also be used as a constituent of fragrance compositions (fragrance compositions) and due to its specific effectiveness as
• mast cells can give a perfumed finished product an anti-allergic or antipruritic effect.
• a particularly preferred fragrance composition comprises (a) a sensorially effective amount of a fragrance, (b) an antiallergic or itch-relieving amount of one or more compounds of formula 1 and (c) optionally one or more carriers and / or additives. Since the proportion of perfume in a finished cosmetic product is often in the range of about 1% by weight, a perfume which contains a compound of the formula 1 according to the invention is. preferably consist of about 0.1-10 wt .-% of one or more compounds of formula 1. It has proven to be particularly advantageous that the substances of formula 1 have only a weak intrinsic odor or are even completely odorless; because this property predestines it especially for use as inhibitors of substance P-induced release of histamine from mast cells in a fragrance composition.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Dermatology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Birds (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Pulmonology (AREA)
• Immunology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cosmetics (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=32240379

Family Applications (1)

Country Status (9)

Cited By (96)

Families Citing this family (75)

Citations (3)

Family Cites Families (22)

• 2002
  • 2002-11-25 DE DE10254872A patent/DE10254872A1/de not_active Withdrawn
• 2003
  • 2003-11-20 BR BRPI0307117A patent/BRPI0307117B8/pt not_active IP Right Cessation
  • 2003-11-20 KR KR1020057009267A patent/KR20050085127A/ko not_active Ceased
  • 2003-11-20 JP JP2004554400A patent/JP2006514931A/ja active Pending
  • 2003-11-20 CN CN200910173877XA patent/CN101683310B/zh not_active Expired - Lifetime
  • 2003-11-20 EP EP03780002.6A patent/EP1567143B1/de not_active Expired - Lifetime
  • 2003-11-20 CN CNB2003801040167A patent/CN100548289C/zh not_active Expired - Lifetime
  • 2003-11-20 AU AU2003288126A patent/AU2003288126A1/en not_active Abandoned
  • 2003-11-20 US US10/535,985 patent/US8203016B2/en active Active
  • 2003-11-20 WO PCT/EP2003/012990 patent/WO2004047833A2/de not_active Ceased
• 2010
  • 2010-08-05 JP JP2010176413A patent/JP5467014B2/ja not_active Expired - Lifetime
• 2012
  • 2012-06-15 US US13/524,374 patent/US8409552B2/en not_active Expired - Lifetime

Patent Citations (3)

Non-Patent Citations (12)

Also Published As

Similar Documents

Legal Events